Literature DB >> 10553701

Activity of newer fluoroquinolones in vitro against gram-positive bacteria.

G M Eliopoulos1.   

Abstract

Several newer fluoroquinolones, which have been recently introduced or are under investigation, display substantially greater potency against gram-positive organisms than the older generation agents of this class. Nevertheless, for problem organisms including methicillin-resistant strains of Staphylococcus aureus and many Enterococcus faecium, concentrations of newer antimicrobials required to inhibit 90% of organisms in the collections studied remain above those that are projected to be achievable with clinical use. Nevertheless, enhanced potency of several newer quinolones may result in a favourable pharmacodynamic profile leading to improved outcomes against gram-positive infections and possibly to the delayed or diminished emergence of resistance to these agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553701     DOI: 10.2165/00003495-199958002-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  37 in total

1.  In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.

Authors:  D Felmingham; M J Robbins; K Ingley; I Mathias; H Bhogal; A Leakey; G L Ridgway; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

2.  Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.

Authors:  B A Cunha; S M Qadri; Y Ueno; E A Walters; P Domenico
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

3.  In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

Authors:  M Souli; C B Wennersten; G M Eliopoulos
Journal:  Int J Antimicrob Agents       Date:  1998-04       Impact factor: 5.283

4.  In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.

Authors:  K V Rolston; D H Ho; B LeBlanc; H Streeter; T Dvorak
Journal:  J Antimicrob Chemother       Date:  1997-06       Impact factor: 5.790

5.  In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.

Authors:  S A Marshall; R N Jones; P R Murray; J A Washington; S D Allen; E H Gerlach; M E Erwin
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

6.  In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.

Authors:  F Marco; R N Jones; D J Hoban; A C Pignatari; N Yamane; R Frei
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

7.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

8.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  The in-vitro activity of two new quinolones: rufloxacin and MF 961.

Authors:  R Wise; J M Andrews; R Matthews; M Wolstenholme
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

10.  In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.

Authors:  T Nakane; S Iyobe; K Sato; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

View more
  3 in total

Review 1.  Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Authors:  K Poole
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Photodegradation of moxifloxacin in aqueous and organic solvents: a kinetic study.

Authors:  Iqbal Ahmad; Raheela Bano; Syed Ghulam Musharraf; Sofia Ahmed; Muhammad Ali Sheraz; Qamar ul Arfeen; Muhammad Salman Bhatti; Zufi Shad
Journal:  AAPS PharmSciTech       Date:  2014-08-20       Impact factor: 3.246

3.  Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Authors:  Myriam V Valenzuela; Mirian Domenech; Patricia Mateos-Martínez; Fernando González-Camacho; Adela G de la Campa; Maria Teresa García
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.